Tandem Diabetes Care and Solana Compared in Critical Analysis

Which small-cap medical company is the better stock investment?

Feb. 24, 2026 at 2:48am

Got story updates? Submit your updates here. ›

A critical analysis compares the performance and prospects of two small-cap medical companies, Tandem Diabetes Care (NASDAQ:TNDM) and Solana (NASDAQ:HSDT). The analysis examines factors like volatility, valuation, profitability, analyst recommendations, and institutional ownership to determine which stock is the better investment.

Why it matters

This analysis provides investors with a detailed comparison of two emerging medical technology companies, helping them make more informed decisions about where to allocate their capital in the small-cap healthcare sector.

The details

The analysis finds that Tandem Diabetes Care has higher revenue but lower earnings per share compared to Solana. However, Tandem Diabetes Care is trading at a lower price-to-earnings ratio, indicating it is currently more affordable. Analysts also have a stronger consensus rating and higher price target for Tandem Diabetes Care compared to Solana. Additionally, Tandem Diabetes Care has stronger net margins, return on equity, and return on assets. The analysis also notes that Tandem Diabetes Care has stronger institutional ownership, which is seen as an indicator of long-term outperformance.

  • The analysis was published on February 24, 2026.

The players

Tandem Diabetes Care, Inc.

A medical device company that designs, develops, and commercializes technology solutions for people living with diabetes, including its flagship t:slim X2 insulin delivery system.

Solana

A small-cap medical company that competes with Tandem Diabetes Care in the diabetes technology space.

Got photos? Submit your photos here. ›

The takeaway

This analysis suggests that Tandem Diabetes Care may be the more favorable investment compared to Solana, based on its stronger financial performance, more positive analyst sentiment, and greater institutional backing. However, investors should continue to monitor both companies' progress in the competitive diabetes technology market.